P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.

• Serageldin Kamel,
• Lucia Martiniova,
• Eslam Aboismail,
• Joo Schmidt,
• Sairah Ahmed,
• Ranjit Nair,
• Raphael E. Steiner,
• Michael L. Wang,
• Sarita Soebianto,
• Gregory Ravizzini,
• Tinsu Pan,
• Hun Ju Lee

Affiliations

Serageldin Kamel

1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA

Lucia Martiniova

2 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, TX, USA

Eslam Aboismail

1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA

Joo Schmidt

1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA

Sairah Ahmed

1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA

Ranjit Nair

1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA

Raphael E. Steiner

1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA

Michael L. Wang

1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA

Sarita Soebianto

3 Department of Diagnostic Imaging-Education, The University of Texas MD Anderson Cancer Center, TX, USA

Gregory Ravizzini

4 Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, TX, USA

Tinsu Pan

5 Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, TX, USA

Hun Ju Lee

1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA